secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116774
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q3 2024: YUPELRI sales record $62.2M (+7%); net loss widens; board forms strategic review
--------------------------------------------------------------------------------

- Total revenue $16.9M (Viatris collab); implied YUPELRI net sales $62.2M all-time high (7% YoY, 14% QoQ).
- Net loss $12.7M vs $9.0M YoY; non-GAAP net loss from operations $2.9M vs $0.7M.
- TRELEGY milestone: Q4 sales ~$260M needed for $25M payment, ~$610M for $50M; YTD sales $2.6B.
- Board forms Strategic Review Committee to assess alternatives to unlock shareholder value.
- CYPRESS (ampreloxetine) open-label enrollment on track for mid-2025 completion; data ~6 months later.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924116774/0001104659-24-116774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924116774/tm2428109d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer